Drug Database
Back to search

Poland· PL-100247950

Nulojix

A belatacept product containing belataceptum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.

ATC L04AA28

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNulojixATCL04AA28REGISTER NO.PL-100247950PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about belataceptumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Belatacept is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AA28 (belatacept), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search belatacept products by name

Belatacept · ATC L04AA28

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of belatacept costs, country by country.

Normalised to the WHO defined daily dose (12.5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Belatacept · price per daily dose (12.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$32.75
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Belataceptum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
L04AA28
ATC class
Belatacept
Defined daily dose
12.5 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990866557
  • gtin
    05909990866564

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

62 interactions on record for belatacept.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check belatacept against other medicinesHow interaction checks work

Belatacept · interactions on record

62 records

  • 29 severe
  • 26 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Belatacept in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All belatacept products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Nulojix
  • Liechtenstein · Nulojix
  • Norway · Nulojix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/44910e41-afbc-4f4a-b6ad-56e8ff80ca41
GET /v1/drugs/44910e41-afbc-4f4a-b6ad-56e8ff80ca41?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909990866557 ¦ Rpz ¦ EU/1/11/694/001 ¦ 66347\n1 fiol. 20 ml + 1 strzyk.\n05909990866564 ¦ Rpz ¦ EU/1/11/694/002 ¦ 66348\n2 fiol. 20 ml + 2 strzyk.",
  "substance": "Belataceptum 250 mg",
  "common_name": "Belataceptum",
  "pl_product_id": "100247950",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about belatacept.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console